Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

被引：1
|
作者：
Yamaguchi, Teppei [1 ]
Hida, Toyoaki [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷 / 08期
关键词：
PHASE-III; MAINTENANCE BEVACIZUMAB; CHEMOTHERAPY; COMBINATION; NIVOLUMAB; DOCETAXEL; EFFICACY; THERAPY; SAFETY;
D O I：
10.21037/tcr.2019.12.57
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E11 / E14
页数：4
相关论文
共 50 条
  • [31] First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
    Yang, Zhiguang
    Zhu, Yumei
    Xiang, Guiyuan
    Hua, Tiantian
    Ni, Jun
    Zhao, Jie
    Lu, Yun
    Wu, Yingyu
    Chang, Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1061 - 1067
  • [32] Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study
    Yin, Chen
    Zou, Guo-Rong
    He, Yan
    Li, Juan
    Yan, Hao-Wen
    Su, Zhen
    Cao, Xiao-Long
    Li, Xiao-Bing
    JOURNAL OF THORACIC DISEASE, 2023, 15 (04) : 1838 - 1847
  • [33] Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen
    Hao, Xuezhi
    Zhu, Yixiang
    Mu, Yuxin
    Wang, Shouzheng
    Li, Junling
    Xing, Puyuan
    JOURNAL OF CANCER, 2020, 11 (21): : 6421 - 6428
  • [34] The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias
    Fujita, Tetsuo
    Hiroishi, Takuma
    Shikano, Kohei
    Yanagisawa, Asako
    Hayama, Noriko
    Amano, Hiroyuki
    Nakamura, Makoto
    Hirano, Satoshi
    Tabeta, Hiroshi
    Nakamura, Sukeyuki
    INTERNAL MEDICINE, 2018, 57 (13) : 1827 - 1832
  • [35] Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer
    Parody-Rua, Elizabeth
    Augusto Guevara-Cuellar, Cesar
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 93 - 98
  • [36] A Phase I Trial of Weekly Nab-paclitaxel Plus Carboplatin With Thoracic Radiotherapy for Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Sakai, Mizu
    Anabuki, Kazuki
    Takamatsu, Kazufumi
    Mukaida, Kenichi
    Kobayashi, Kana
    Yamagami, Takuji
    Yokoyama, Akihito
    IN VIVO, 2024, 38 (01): : 259 - 263
  • [37] Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
    Laktionov, K.
    Smolin, A.
    Stroyakovskiy, D.
    Moiseenko, V.
    Dvorkin, M.
    Andabekov, T.
    Cheng, Y.
    Liu, B.
    Kozlov, V.
    Odintsova, S.
    Dvoretsky, S.
    Mochalova, A.
    Urda, M.
    Yi, T.
    Li, X.
    Laszlo, U.
    Mueller, V.
    Bogos, K.
    Fadeeva, N.
    Musaev, G.
    Liu, Q.
    Kirtbaya, D.
    Shi, J.
    Gladkov, O.
    Narimanov, M.
    Semiglazova, T.
    Khasanova, A.
    Chovanec, J.
    Andrasina, I
    Szabova, A.
    Rosinska, O.
    Sudekova, D.
    Zsolt, P. -s.
    Ran, F.
    Sun, M.
    Jiang, O.
    Chen, R.
    Zhao, E.
    Liu, C.
    Tan, W.
    Pirmagomedov, A.
    Poddubskaya, E.
    Kislov, N.
    Shumskaya, I.
    Sorokina, I.
    Zinkina-Orikhan, A.
    Linkova, Yu.
    Fogt, S.
    Liaptseva, D.
    Siliutina, A.
    EUROPEAN JOURNAL OF CANCER, 2025, 217
  • [38] Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
    Govindan, Ramaswamy
    Lind, Mike
    Insa, Amelia
    Khan, Saad A.
    Uskov, Dmitry
    Tafreshi, Ali
    Guclu, Salih
    Bar, Jair
    Kato, Terufumi
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Hansen, Olfred
    Biesma, Bonne
    Kundu, Madan G.
    Dunbar, Martin
    He, Lei
    Ansell, Peter
    Sehgal, Vasudha
    Huang, Xin
    Glasgow, Jaimee
    Bach, Bruce A.
    CLINICAL LUNG CANCER, 2022, 23 (03) : 214 - 225
  • [39] Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent
    Saxena, Ashish
    Schneider, Bryan J.
    Christos, Paul J.
    Audibert, Lauren F.
    Cagney, Jennifer M.
    Scheff, Ronald J.
    MEDICAL ONCOLOGY, 2016, 33 (02) : 1 - 9
  • [40] What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
    Ricciuti, Biagio
    Awad, Mark M.
    CANCER JOURNAL, 2020, 26 (06) : 485 - 495
12345